Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

George W. Merck

Merck & Co., Inc.

LégiaPark is an economic activity center dedicated to hosting companies active in life sciences. It provides a suitable environment for research, production, or commercialization activities.

LégiaPark

Solbosch provides a variety of medical and paramedical specialties. It is equipped with a viral air purifier.

Solbosch

Adalvo is a global pharmaceutical company with a purpose to make a difference for patients around the world, driven by a smart collaboration network and a commitment to deliver quality differentiated products and services to its partners. Self-described as being 'always on target.'

Adalvo

Merck Animal Health

Merck Canada

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. 

This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

NGM Biopharmaceuticals

Just - Evotec Biologics

eASIC

SAB Biotherapeutics

Alnylam Pharmaceuticals

Hangzhou Just Biotherapeutics (Just China)

Sutro Biopharma

Themis Bioscience

Seagen

Private Capital Advisors

Gavi, the Vaccine Alliance

Merck

A diverse workforce is not only fundamental to our company's future success, but it's also a part of our rich history. 
 
🧬 Susan Jenkins paved the way for black women in science at Merck, as part of the team that first synthesized ribonuclease. She also served as a black university liaison in our company's corporate equal employment affairs department.
 
⚾️ After the integration of Major league Baseball, star pitcher, Jimmy Dean, famous for his sinker-ball found a second career at Merck until retiring from his position as a technical analyst in 1990.
 
👥 In 1968, Merck appointed Lawrence “Larry” Branch vice president of personnel relations, responsible for employment, training and promotion of persons from all minority groups. This new position marked the beginnings of Merck’s Office of Equal Employment Affairs — one of the first in the country to prioritize equity for black employees.
 
We remain committed to attracting and developing diverse talent during #BlackHistoryMonth and every day. Check out open roles to join our team: http://merck.us/49Qmxqe

Wife, mother, and employee, Gina Esposito, MSM-HC, had 20 years of normal cervical screenings before she was diagnosed with HPV-related #cervical precancer. Today she feels empowered to share her story with colleagues and encourage others to take care of their health.

This #BlackHistoryMonth, we want to raise awareness of the importance of diversity in clinical trials and our ongoing efforts to increase participation from communities that have historically been underrepresented in research. Hear from Ashley C. Moultrie, director of diversity & community engagement, on why it should be prioritized and the positive impact it can have on our efforts to help achieve health equity.

Heart failure impacts more than 6 million Americans. Robin and Ray, active members with The Mended Hearts, Inc., are living with the condition. Watch to learn about their experiences.

We’re proud to be one of Fortune's World’s Most Admired Companies for 2024, ranking No. 3 in the pharmaceuticals industry for the second year in a row! We’re grateful for the ongoing dedication of our colleagues, whose support has enabled us to achieve this recognition. 

Interested in joining one of the #MostAdmiredCos? See open roles at our company: https://lnkd.in/eSABXQ3

Through mentorship, education, and representation, let's empower women to explore science and technology. In honor of this #IDWGS, we spoke to three scientists at our company about how mentorship is helping fuel the next generation of #WomenInScience.

We’re proud to be named No. 1 in the pharmaceuticals and biotech industry for the fourth year in a row and No. 25 overall on CNBC and JUST Capital’s list of America’s Most JUST Companies. See open roles at our company to join us in helping to create a safer, healthier and more sustainable world for people and communities everywhere: https://lnkd.in/eSABXQ3 #MostJUST

Today we announce the upcoming retirement of EVP and Chief Human Resources Officer Steve Mizell. Betty Larson, a leader with more than 20 years in health care and human resources, will become our EVP and CHRO effective April 8.

We’re following the science this #WorldCancerDay as we work to discover innovations that can help more people no matter what stage of cancer they have, or so they may never be diagnosed at all.

Rob Davis, chairman and CEO, on our Q4 and full-year 2023 #earnings: http://merck.us/3HJtT2M

Metric
Company Name	Merck & Co., Inc.	LégiaPark	Solbosch	Adalvo
Symbol	MRK
MSH ID	COM:MERCK	BE:LEGIAPARK	BE:SOLBOSCH	COM:ADALVO
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Commercial & Professional Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Drug Manufacturers - General	Life Sciences	Healthcare	Pharmaceuticals
Country	US	BE	BE	UK
Stage	Post-IPO Equity
Employee Count	70K
Website	merck.com	legiapark.be	solbosch.be	adalvo.com
LinkedIn	merck	l%C3%A9giapark	le-solbosch
Founders

Metric
Market Cap	322.43B
Enterprise Value
Monthly Web Traffic	1.08M
Web Traffic Growth	0.20
Valuation
Raised Capital	586K

Metric
Revenue	59.87B
Revenue (LTM)
Revenue (NTM)
Gross Profit	43.89B
EBITDA	6.85B
Operating Income	2.98B
Net Income	365M
EPS	0.14
Diluted EPS	0.14
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.76
Operating Profit Margin	0.28
EBITDA Margin	0.11
Net Profit Margin	0.22
Return on Equity	0.35
Return on Assets	0.14
Return on Capital Employed	0.24

COM:MERCK

Merck & Co., Inc. (MSD outside of the U.S. and Canada)

Last Close

99.86

22/11 21:00

Market Cap

322.43B

Beta: -

Volume Today

14.03M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	69.75
P/B Ratio	7.79
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.48
EV Multiple	50.06

Metric
Days Sales Outstanding	63.96
Days Payables Outstanding	79.58
Days Inventory Outstanding	160.67
Operating Cycle	234.12
Cash Conversion Cycle	147.39
Asset Turnover	0.62

Metric
Operating Cash Flow	13.01B
Free Cash Flow	9.14B
Cash Flow to Debt	0.44
Operating Cash Flow/Sales	0.27
Free Cash Flow Yield	0.04

Metric
Cash & Equivalents	6.91B
Accounts Receivable	-1.15B
Inventory	6.36B
Goodwill	21.20B
Debt to Capitalization	0.48
Debt to Assets	0.33
Current Ratio	1.38
Quick Ratio	1.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.42
SG&A to Revenue